. Inhibition curves of SCEI 4 and Bortezomib towards APEH and chymotrypsin-like (CT-like) subunit (β5) of proteasome; (A) Inhibition kinetic analyses of SCEI 4 and Bortezomib towards porcine APEH, using Ac-Ala-pNA as substrate; (B) inhibition kinetics by increasing concentrations of SsCEI 4 towards the CT-like (β5 subunit) activity of proteasome, using Suc-LLVY-AMC as substrate; (C) dose-dependent inhibitory effect of Bortezomib on CT-like activity of proteasome. Enzymes incubated without inhibitors were used as controls. The commercially available 20S proteasome from human erythrocytes and APEH from porcine liver were used to detect the inhibitory effects of the different compounds. The hyperbolic curves indicate the best fits for the data obtained, with IC50 values calculated from the graphs by SigmaPlot 10.0 software. Results are presented as the mean ± standard deviation (SD) of analyses from three independent experiments. SD values lower than 5% were not shown.
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